Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

urothelial carcinoma

  • You have access
    Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study
    NOBUKI FURUBAYASHI, AKINORI MINATO, TOSHIHISA TOMODA, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, YUSUKE HARAGUCHI, TOSHIKI KOGA, KENICHI HARADA, KENTARO KUROIWA, NAOHIRO FUJIMOTO, MOTONOBU NAKAMURA and Uro-Oncology Group in Kyushu (UROKYU)
    Anticancer Research April 2024, 44 (4) 1675-1681; DOI: https://doi.org/10.21873/anticanres.16966
  • You have access
    Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study
    NOBUKI FURUBAYASHI, AKINORI MINATO, TOSHIHISA TOMODA, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, YUSUKE HARAGUCHI, TOSHIKI KOGA, KENTARO KUROIWA, NAOHIRO FUJIMOTO and MOTONOBU NAKAMURA
    Anticancer Research December 2023, 43 (12) 5689-5698; DOI: https://doi.org/10.21873/anticanres.16774
  • You have access
    Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study
    NOBUKI FURUBAYASHI, AKINORI MINATO, TAKAHITO NEGISHI, NAOTAKA SAKAMOTO, YOOHYUN SONG, YOSHIFUMI HORI, TOSHIHISA TOMODA, HIROYUKI MASAOKA, MIRII HARADA, SHINGO TAMURA, HIROKI KOBAYASHI, KAEDE MORIHARA, KENTARO KUROIWA, NARIHITO SEKI, NAOHIRO FUJIMOTO and MOTONOBU NAKAMURA
    Anticancer Research October 2023, 43 (10) 4701-4708; DOI: https://doi.org/10.21873/anticanres.16666
  • Open Access
    Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World
    AKINORI MINATO, RIEKO KIMURO, DAICHI OHNO, KENTAROU TANIGAWA, KEISUKE KURETAKE, TAKUO MATSUKAWA, TOMOHISA TAKABA, KAZUMASA JOJIMA, MIRII HARADA, KATSUYOSHI HIGASHIJIMA, YUJIRO NAGATA, IKKO TOMISAKI, KENICHI HARADA, NAOHIRO FUJIMOTO and HIROSHI MIYAMOTO
    Anticancer Research September 2023, 43 (9) 4055-4060; DOI: https://doi.org/10.21873/anticanres.16594
  • You have access
    Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma
    TAKESHI SANO, RIHITO AIZAWA, KATSUHIRO ITO, KIYONAO NAKAMURA, TAKASHI OGATA, MASASHI TAKEDA, AKIHIRO HAMADA, TAKASHI MATSUOKA, JIN KONO, YUKI KITA, KIMIHIKO MASUI, TAKAYUKI GOTO, ATSURO SAWADA, SHUSUKE AKAMATSU, OSAMU OGAWA, TAKASHI MIZOWAKI and TAKASHI KOBAYASHI
    Anticancer Research May 2023, 43 (5) 2119-2126; DOI: https://doi.org/10.21873/anticanres.16373
  • Open Access
    Expression of Eukaryotic Translation Initiation Factors in the Urothelial Carcinoma of the Bladder
    JETON LUZHA, NORBERT NASS, PIOTR CZAPIEWSKI, NICOLAS SCHROEDER, THOMAS KALINSKI, MARTIN SCHOSTAK, CHRISTOPH SCHATZ, BURKHARD JANDRIG and JOHANNES HAYBAECK
    Anticancer Research April 2023, 43 (4) 1437-1448; DOI: https://doi.org/10.21873/anticanres.16292
  • You have access
    Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells
    SAN-YUAN CHEN, CHUN-NUN CHAO, HSIN-YI HUANG, PEI-WEN ZHAO and CHIUNG-YAO FANG
    Anticancer Research March 2023, 43 (3) 1175-1184; DOI: https://doi.org/10.21873/anticanres.16263
  • You have access
    First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study
    JIAN-RI LI, SHIAN-SHIANG WANG, KEVIN LU, CHAUN-SHU CHEN, CHEN-LI CHENG, SHENG-CHUN HUNG, KUN-YUAN CHIU, CHIANN YI HSU and CHENG-KUANG YANG
    Anticancer Research March 2023, 43 (3) 1331-1339; DOI: https://doi.org/10.21873/anticanres.16281
  • You have access
    Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
    IKKO TOMISAKI, MIRII HARADA, SHIGERU SAKANO, MICHIKAZU TERADO, RYOICHI HAMASUNA, SHUJI HARADA, HIROOMI MATSUMOTO, SOICHIRO AKASAKA, YUJIRO NAGATA, AKINORI MINATO, KEN-ICHI HARADA and NAOHIRO FUJIMOTO
    Anticancer Research January 2023, 43 (1) 269-274; DOI: https://doi.org/10.21873/anticanres.16159
  • You have access
    Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer
    SATOSHI INOUE, NAOTO SASSA, HIDEJI KAWANISHI, YURI YUGUCHI, TOMOHIDE SUZUKI, JUN NAGAYAMA, HIROTAKA MATSUI, YUDAI MIYATA, YUYA SOEDA, KOSUKE TOCHIGI, YUSHI YAMAUCHI, MOTOHIRO MAEDA, IKUO KOBAYASHI, RYOHEI HATTORI, YOSHIHISA MATSUKAWA and MASASHI KATO
    Anticancer Research July 2022, 42 (7) 3627-3636; DOI: https://doi.org/10.21873/anticanres.15851

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire